Related Experiment Video
Updated: Mar 27, 2026
A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
Retrospective Analysis of the Medication Utilization and Clinical Outcomes of Patients Treated with Various Regimens
William D Trombatt1,2, Pamela H Koerner1, Zoie N Craft2
11 Duquesne University Mylan School of Pharmacy, Pittsburgh, PA, USA.
Insights
New hepatitis C virus (HCV) treatments combining sofosbuvir and simeprevir achieved high sustained virologic response (SVR) rates of 86.9% in real-world use. These advanced therapies demonstrated improved tolerability and lower discontinuation rates compared to older treatments.
Area of Science:
- Hepatology
- Infectious Diseases
- Pharmacology
Background:
- Hepatitis C virus (HCV) infection is a major cause of chronic liver disease and liver transplantation in the U.S.
- Over 3.2 million Americans are infected with HCV.
- The 2013 introduction of sofosbuvir and simeprevir significantly improved sustained virologic response (SVR) rates.
Purpose of the Study:
- To assess medication use and clinical outcomes in HCV patients treated with FDA-approved regimens.
- Evaluated combinations including ribavirin, peginterferon, simeprevir, and sofosbuvir.
Main Methods:
- Retrospective review of patient records and clinical assessments from 2014.
- Included patients initiating HCV therapy eligible for SVR.
- Collected data on demographics, genotype, SVR, adverse events, discontinuations, and adherence.
Main Results:
- 367 eligible patients initiated treatment.
- Genotype 1 was most prevalent.
- An overall SVR rate of 86.9% was achieved, consistent with clinical trials.
- Adverse events were tolerable, and discontinuation rates were lower than with prior therapies.
Conclusions:
- Real-world data confirm the high efficacy of newer HCV treatment regimens.
- These advanced therapies offer improved tolerability and adherence.
- The findings support the use of sofosbuvir and simeprevir combinations for HCV treatment.
Background:
The hepatitis C virus (HCV) is the most common chronic blood-borne infection and the leading cause of liver transplantation in the United States. There are approximately 3.2 million people currently infected with HCV in the United States. In late 2013, the introduction of sofosbuvir and simeprevir represented a critical advancement in the treatment of HCV by improving sustained virologic response (SVR) rates.
Purpose:
The purpose of this study was to evaluate medication utilization and clinical outcomes of patients with HCV who were treated with any Food and Drug Administration-approved combination of ribavirin, peginterferon products, simeprevir, and sofosbuvir.
Methods:
Prescription records and clinical assessment forms of patients who started HCV therapy and were eligible for SVR between January 1, 2014, and December 31, 2014, were retrospectively reviewed. Data collection included patient demographics, genotype, SVR, patient-reported adverse events, discontinuations, and adherence markers.
Results:
A total of 367 eligible patients were identified who had initiated treatment during the study period. Genotype 1 was the most common genotype, and an overall SVR rate of 86.9% was observed. Results were similar to those seen in phase III clinical trials. In addition, adverse events of these medications were more tolerable, and discontinuation rates were lower than with previous therapies.
Related Concept Videos
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
01:16Hepatic Drug Excretion: Influencing Factors
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...